0000000000108853

AUTHOR

A. Dolce

showing 4 related works from this author

Matrix metalloproteinases production in malignant pleural effusions after talc pleurodesis

2003

SUMMARY In this study we have evaluated the modifications of matrix metalloproteinases (MMPs) in malignant pleural fluids taken from patients suffering from lung cancer and treated with intrapleural talc instillation to induce pleurodesis. Furthermore, we have analysed the variations of some inflammatory mediators (C-reactive protein, α-1 antitrypsin) and of a protein (plasminogen) involved in MMP activation. In all patients the clinical improvement after talc pleurodesis was followed by a reduction in MMP-1, TIMP-1, C-reactive protein, α-1 antitrypsin and plasminogen activity. Furthermore, MMP-9 levels were variable; in fact, in some patients they were high at the beginning of treatment, i…

MalePathologymedicine.medical_specialtyPleural effusionmedicine.medical_treatmentImmunologyMatrix metalloproteinaseTalcStatistics NonparametricClinical StudiesHumansImmunology and AllergyMedicineLung cancerPleurodesisAgedTissue Inhibitor of Metalloproteinase-1business.industryTalc pleurodesisA proteinPlasminogenMiddle Agedmedicine.diseaseMatrix MetalloproteinasesPleural Effusion MalignantC-Reactive ProteinMatrix Metalloproteinase 9Talcalpha 1-AntitrypsinImmunologyPleural fluidFemaleMatrix Metalloproteinase 1businessPleurodesismedicine.drugClinical and Experimental Immunology
researchProduct

Replacement Therapy for Minor Surgery and Invasive Procedures in Factor VII Deficiency: The STER Experience

2011

Adverse events Inherited Factor VII deficiency
researchProduct

Comunicazione orale

2011

Bleeding PhenotypeFactor VII deficiency
researchProduct

Bleeding symptoms at disease presentation and prediction of ensuing bleeding in inherited FVII deficiency.

2012

SummaryIndividuals with inherited factor VII (FVII) deficiency display bleeding phenotypes ranging from mild to severe, with 30% of patients having always been asymptomatic (non-bleeding). In 626 FVII-deficient individuals, by analysing data from the International Factor VII (IF7) Registry and the Seven Treatment Evaluation Registry (STER), we determined whether bleeding type at disease presentation and FVII coagulant activity (FVIIc) predict ensuing bleeds. At disease presentation/diagnosis, 272 (43.5%) individuals were non-bleeding, 277 (44.2%) had minor bleeds, and 77 (12.3%) had major bleeds. During a median nine-year index period (IP) observation, 87.9% of non-bleeding individuals at p…

RegistrieMalePediatricsFactor VII DeficiencyInternational CooperationAsymptomatic individual030204 cardiovascular system & hematologychemistry.chemical_compound0302 clinical medicineRetrospective StudieAge FactorRegistriesYoung adultChildClinical Trials as TopicHematologyFactor VIIAge FactorsHematologyFactor VIIMiddle AgedPhenotypeTreatment OutcomeChild PreschoolFemalePresentation (obstetrics)medicine.symptomHumanAdultQuality ControlRiskmedicine.medical_specialtyAdolescentHemorrhageAsymptomaticMajor bleed03 medical and health sciencesYoung AdultInternal medicinemedicineHumansRetrospective StudiesModels Statisticalbusiness.industryMinor bleedInfantRetrospective cohort studychemistryDisease PresentationRelative riskbusiness030215 immunologyThrombosis and haemostasis
researchProduct